Senores Pharmaceuticals Ltd (SENORES) Q4FY26 Management Mirror - Mar-2026 Qtr
Revenue & Profitability Growth
Management upgraded FY27 (Mar'27) expectations in the Mar'26 Qtr, explicitly targeting revenue growth of 30% to 40% and PAT growth of 50% to 60%, stepping up from the Dec'25 Qtr guidance of 25%-plus top-line growth and the Sep'25 Qtr baseline of a 25% to 30% long-term CAGR. [Status: Upgraded]
4 more themes on the ELITE plan.